Peter G. Linde
Corporate Officer/Principal bei Walden Biosciences, Inc.
Profil
Peter G.
Linde is currently the Chief Medical Officer at Walden Biosciences, Inc. He previously worked as the Senior Director-Clinical Development at FibroGen, Inc. and as the Vice President-Medical Research at Acceleron Pharma, Inc. From 2020 to 2021, he served as the Chief Medical Officer at Morphic Holding, Inc. Linde received his undergraduate degree from the Massachusetts Institute of Technology.
Aktive Positionen von Peter G. Linde
| Unternehmen | Position | Beginn |
|---|---|---|
Walden Biosciences, Inc.
 Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | Corporate Officer/Principal | 11.10.2022 |
Ehemalige bekannte Positionen von Peter G. Linde
| Unternehmen | Position | Ende |
|---|---|---|
| MORPHIC HOLDING, INC. | Chief Tech/Sci/R&D Officer | 31.12.2021 |
| FIBROGEN, INC. | Corporate Officer/Principal | - |
| ACCELERON PHARMA INC. | Corporate Officer/Principal | - |
Ausbildung von Peter G. Linde
| Massachusetts Institute of Technology | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| MORPHIC HOLDING, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
Walden Biosciences, Inc.
Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | Health Services |
